Who makes combination therapy with MEKi-HCQ?

combination therapy with MEKi-HCQ is developed by Mandana Kamgar, MD.

What development phase is combination therapy with MEKi-HCQ in?

combination therapy with MEKi-HCQ is in Phase 2.

Last reviewed 2026-04-19 · How we verify

combination therapy with MEKi-HCQ

Mandana Kamgar, MD · Phase 2 active Small molecule

At a glance

Generic name	combination therapy with MEKi-HCQ
Also known as	mitogen-activated extracellular signal-regulated kinase inhibitor with hydroxychloroquine
Sponsor	Mandana Kamgar, MD
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

combination therapy with MEKi-HCQ CI brief — competitive landscape report
combination therapy with MEKi-HCQ updates RSS · CI watch RSS
Mandana Kamgar, MD portfolio CI